The estimated Net Worth of Bernard Coulie is at least $15.2 Million dollars as of 10 July 2024. Dr Coulie owns over 38,710 units of Pliant Therapeutics stock worth over $5,920,795 and over the last 4 years he sold PLRX stock worth over $8,344,151. In addition, he makes $895,266 as Pres and CEO & Director at Pliant Therapeutics.
Dr has made over 21 trades of the Pliant Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 38,710 units of PLRX stock worth $447,488 on 10 July 2024.
The largest trade he's ever made was selling 70,150 units of Pliant Therapeutics stock on 17 July 2023 worth over $1,263,402. On average, Dr trades about 18,682 units every 50 days since 2020. As of 10 July 2024 he still owns at least 482,936 units of Pliant Therapeutics stock.
You can see the complete history of Dr Coulie stock trades at the bottom of the page.
Dr. Bernard Coulie M.B.A., M.D., MBA, Ph.D. is the Pres, CEO & Director at Pliant Therapeutics.
As the Pres and CEO & Director of Pliant Therapeutics, the total compensation of Dr D at Pliant Therapeutics is $895,266. There are no executives at Pliant Therapeutics getting paid more.
Dr D is 55, he's been the Pres and CEO & Director of Pliant Therapeutics since . There are 2 older and 2 younger executives at Pliant Therapeutics. The oldest executive at Pliant Therapeutics, Inc. is Dr. Ãric Lefebvre M.D., 57, who is the Chief Medical Officer.
Bernard's mailing address filed with the SEC is C/O PLIANT THERAPEUTICS, INC., 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 4 years, insiders at Pliant Therapeutics have traded over $16,925,448 worth of Pliant Therapeutics stock. The most active insiders traders include Group, Llc Green Jeremy Red..., Rock Ventures Iii, L.P.Thir..., and Thomas A Mccourt. On average, Pliant Therapeutics executives and independent directors trade stock every 24 days with the average trade being worth of $221,612. The most recent stock trade was executed by Eric Lefebvre on 10 July 2024, trading 12,319 units of PLRX stock currently worth $142,408.
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Pliant Therapeutics executives and other stock owners filed with the SEC include: